Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 101–200 of 1,004
Damask, A., Steg, P. G., Schwartz, G. G., Szarek, M., Hagström, E., Badimon, L., Chapman, M. J., Boileau, C., Tsimikas, S., Ginsberg, H. N., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044434 · Cited by 242
Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.03.019 · Cited by 240
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01634-w · Cited by 239
Genetics of Common, Complex Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2019) · Cell · doi:10.1016/j.cell.2019.02.015 · Cited by 239
Large-Scale Gene-Centric Analysis Identifies Novel Variants for Coronary Artery Disease
The IBC 50K CAD Consortium (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002260 · Cited by 237
“The array’s potential to identify disease-associated lower frequency variants has been demonstrated by previous identification of strong independent associations with 2 variants in the LPA gene rs3798220 (minor allele frequency 2%), and rs10455872 (7%) - and CAD risk [11].”
BackgroundSaleheen, D., Haycock, P. C., Zhao, W., Rasheed, A., Taleb, A., Imran, A., Abbas, S., Majeed, F., Akhtar, S., Qamar, N., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30088-8 · Cited by 237
Recent advances in physiological lipoprotein metabolism
Ramasamy, I. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0358 · Cited by 235
“Single nucleotide polymorphisms in the LPA gene locus and repeat polymorphisms in the promoter region of the LPA gene which increase Lp(a) levels have been shown to be associated with increased CHD risk [169, 170].”
BackgroundLipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease
Tsimikas, S., & Hall, J. L. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.038 · Cited by 234
“Finally, Lp(a) levels were not measured, which would have been useful to tease out the effect of the SNPs on Lp(a) levels and their respective effects on CVD risk.”
BackgroundInfluentialDominguez-Rodriguez, A., Abreu-Gonzalez, P., Sanchez-Sanchez, J. J., Kaski, J. C., & Reiter, R. J. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00773.x · Cited by 232
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
Kronenberg, F. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6648-3 · Cited by 230
“Besides these well characterized variants several dozens of SNPs in the wider LPA region have recently been brought to the attention of the scientific community [37].”
BackgroundInfluentialRoeters van Lennep, J. E., Tokgözoğlu, L. S., Badimon, L., Dumanski, S. M., Gulati, M., Hess, C. N., Holven, K. B., Kavousi, M., Kayıkçıoğlu, M., Lutgens, E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad472 · Cited by 229
Varvel, S., McConnell, J. P., & Tsimikas, S. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308011 · Cited by 218
“Similarly, in the PROCARDIS study (Precocious Coronary Artery Disease), levels of Lp(a) at which risk accumulated started ≈25 mg/dL and rose linearly with both Lp(a) levels and the number of LPA variant alleles that are known to be associated with increasing Lp(a) levels.(3) In the JUPITER trial (Justification for the…”
Roeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., Breitenberger, P., Leebmann, J., Lehmacher, W., Kamstrup, P. R., Nordestgaard, B. G., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307983 · Cited by 227
“These are all translated and lead to a size polymorphism of apo(a), which is causally associated with Lp(a) concentrations in an inverse manner.4,5 Lp(a) isoforms have been categorized as small (≤22 KIV repeats) or large (>22 KIV repeats) with small isoforms, implying an ≈2-fold higher risk of CVD.6 Sequence variation…”
BackgroundResultInfluentialLamina, C., Kronenberg, F., & for the Lp(a)-GWAS-Consortium (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1041 · Cited by 218
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Blom, D., Seidah, N. G., Honarpour, N., Lira, A., Xue, A., Chiruvolu, P., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101063 · Cited by 218
Lipid parameters for measuring risk of cardiovascular disease
Arsenault, B. J., Boekholdt, S. M., & Kastelein, J. J. P. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.223 · Cited by 225
“By assessing single-nucleotide polymorphisms in candidate genes selected for their potential relevance to CVD, the investigators of the Precocious Coronary Artery Disease (PROCARDIS) stud”
BackgroundCoassin, S., & Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.003 · Cited by 219
“These involve allelic association between SNPs and isoform ranges [23,39,51,88,90,91] (Fig.”
InfluentialKoren, M. J., Giugliano, R. P., Raal, F. J., Sullivan, D., Bolognese, M., Langslet, G., Civeira, F., Somaratne, R., Nelson, P., Liu, T., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007012 · Cited by 218
“This evidence includes Mendelian randomization analyses showing that genetic variations that produce very low levels of LDL-C confer high levels of protection against atherosclerotic complications without known offsetting morbidity or mortality.(16,17) Observations from statin clinical trials provide another compellin…”
BackgroundFrom Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Holmes, M. V., Lange, L. A., Palmer, T., Lanktree, M. B., North, K. E., Almoguera, B., Buxbaum, S., Chandrupatla, H. R., Elbers, C. C., Guo, Y., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.12.014 · Cited by 216
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
O'Donoghue, M. L., Morrow, D. A., Tsimikas, S., Sloan, S., Ren, A. F., Hoffman, E. B., Desai, N. R., Solomon, S. D., Domanski, M., Arai, K., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.042 · Cited by 215
“Lp(a) isoform number or single nucleotide polymorphisms that predict high Lp(a) levels were not measured (3).”
BackgroundAtherosclerotic cardiovascular disease prevention in rheumatoid arthritis
Semb, A. G., Ikdahl, E., Wibetoe, G., Crowson, C., & Rollefstad, S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0428-y · Cited by 214
Mendelian randomization studies in coronary artery disease
Jansen, H., Samani, N. J., & Schunkert, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu208 · Cited by 212
“Interestingly, the LP(a) gene locus was among the first for which genome-wide significant association with CAD was established(47) and a SNP was found to increase both LP(a) levels and CAD risk.(48) A sub-”
BackgroundGurdasani, D., Sjouke, B., Tsimikas, S., Hovingh, G. K., Luben, R. N., Wainwright, N. W. J., Pomilla, C., Wareham, N. J., Khaw, K.-T., Boekholdt, S. M., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.255521 · Cited by 206
Kamstrup, P. R., & Nordestgaard, B. G. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.08.006 · Cited by 206
“In addition, a number of single nucleotide polymorphisms (SNPs) partly tracking the KIV-2 polymorphism are also strongly associated with plasma lipoprotein(a) levels (5,7,8).”
BackgroundNicholls, S. J., Nissen, S. E., Fleming, C., Urva, S., Suico, J., Berg, P. H., Linnebjerg, H., Ruotolo, G., Turner, P. K., & Michael, L. F. (2023) · JAMA · doi:10.1001/jama.2023.16503 · Cited by 206
Smith, J. G., & Gerszten, R. E. (2017) · Circulation · doi:10.1161/circulationaha.116.025446 · Cited by 206
Meta-analysis of gene-level tests for rare variant association
Liu, D. J., Peloso, G. M., Zhan, X., Holmen, O. L., Zawistowski, M., Feng, S., Nikpay, M., Auer, P. L., Goel, A., Zhang, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2852 · Cited by 194
Self-citationLipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis
Nave, A. H., Lange, K. S., Leonards, C. O., Siegerink, B., Doehner, W., Landmesser, U., Steinhagen-Thiessen, E., Endres, M., & Ebinger, M. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.021 · Cited by 200
“genetically determined by an apo(a) size polymorphism encoded in the apolipoprotein(a) gene [5,7].”
BackgroundAssociation of rare and common variation in the lipoprotein lipase gene with coronary artery disease
Khera, A. V., Won, H.-H., Peloso, G. M., O’Dushlaine, C., Liu, D., Stitziel, N. O., Natarajan, P., Nomura, A., Emdin, C. A., Gupta, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.0972 · Cited by 198
Self-citationMehta, A., Vasquez, N., Ayers, C. R., Patel, J., Hooda, A., Khera, A., Blumenthal, R. S., Shapiro, M. D., Rodriguez, C. J., Tsai, M. Y., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.058 · Cited by 182
Santos, R. D., Raal, F. J., Catapano, A. L., Witztum, J. L., Steinhagen-Thiessen, E., & Tsimikas, S. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304549 · Cited by 196
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.248765 · Cited by 194
Nonfasting versus fasting lipid profile for cardiovascular risk prediction
Langsted, A., & Nordestgaard, B. G. (2019) · Pathology · doi:10.1016/j.pathol.2018.09.062 · Cited by 191
Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis
de Boer, L. M., Oorthuys, A. O. J., Wiegman, A., Langendam, M. W., Kroon, J., Spijker, R., Zwinderman, A. H., & Hutten, B. A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab171 · Cited by 179
Keenan, T., Zhao, W., Rasheed, A., Ho, W. K., Malik, R., Felix, J. F., Young, R., Shah, N., Samuel, M., Sheikh, N., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.086 · Cited by 188
“Previously, such an approach has been used to assess the causality of low- and high-density lipoprotein cholesterol (14), triglycerides (15), lipoprotein(a) (16,17), fibrinogen (18), and C-reactive protein in CHD (19).”
MethodSelf-citationOral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial
Nicholls, S. J., Ni, W., Rhodes, G. M., Nissen, S. E., Navar, A. M., Michael, L. F., Haupt, A., & Krege, J. H. (2025) · JAMA · doi:10.1001/jama.2024.24017 · Cited by 154
Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., Holm, H., Patel, R. S., Gudnason, T., Jones, G. T., van Rij, A. M., Eapen, D. J., Baas, A. F., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.078 · Cited by 187
“15 standard deviation units and the risk for CAD y 47% and 68%, respectively (1).”
BackgroundResultInfluentialSelf-citationMack, S., Coassin, S., Rueedi, R., Yousri, N. A., Seppälä, I., Gieger, C., Schönherr, S., Forer, L., Erhart, G., Marques-Vidal, P., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076232 · Cited by 186
“Therefore, carriers of the minor alleles of these two SNPs have higher Lp(a) levels and consequently higher risk of developing coronary disease (10).”
BackgroundResultInfluentialContextualizing selection bias in Mendelian randomization: how bad is it likely to be?
Gkatzionis, A., & Burgess, S. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyy202 · Cited by 182
“We use a single ge-netic instrument that explains 36% of the variation in Lp(a) levels ( a G ¼ ffiffiffiffiffiffiffiffiffiffi 0 : 36 p ); this is the proportion of variation previously reported 31 as explained by the two variants associated with Lp(a) levels that were used in Zewinger et al. ’s analysis.”
Desai, N. R., Kohli, P., Giugliano, R. P., O’Donoghue, M. L., Somaratne, R., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001969 · Cited by 183
Protein-coding repeat polymorphisms strongly shape diverse human phenotypes
Mukamel, R. E., Handsaker, R. E., Sherman, M. A., Barton, A. R., Zheng, Y., McCarroll, S. A., & Loh, P.-R. (2021) · Science · doi:10.1126/science.abg8289 · Cited by 178
Trinder, M., Uddin, M. M., Finneran, P., Aragam, K. G., & Natarajan, P. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.5398 · Cited by 165
Lipoprotein(a) metabolism: Potential sites for therapeutic targets
Hoover-Plow, J., & Huang, M. (2013) · Metabolism · doi:10.1016/j.metabol.2012.07.024 · Cited by 175
van Dijk, R. A., Kolodgie, F., Ravandi, A., Leibundgut, G., Hu, P. P., Prasad, A., Mahmud, E., Dennis, E., Curtiss, L. K., Witztum, J. L., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p030890 · Cited by 167
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“Apo(a) contains multiple kringle domains, defined by 3 disulfide bonds that form a structural motif resembling a Danish pastry.162 Lp(a) also contains proinflammatory oxidized phospholipids (OxPLs), both in the lipid phase and covalently bound to apo(a) via yet-to-be identified amino acids near KIV (kringle-IV) type 1…”
BackgroundRisk factors profile of young and older patients with myocardial infarction
Sagris, M., Antonopoulos, A. S., Theofilis, P., Oikonomou, E., Siasos, G., Tsalamandris, S., Antoniades, C., Brilakis, E. S., Kaski, J. C., & Tousoulis, D. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab264 · Cited by 171
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a)
Zhang, W., Speiser, J. L., Ye, F., Tsai, M. Y., Cainzos-Achirica, M., Nasir, K., Herrington, D. M., & Shapiro, M. D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.016 · Cited by 169
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
Lacaze, P. A., Bakshi, A., Riaz, M., Polekhina, G., Owen, A. J., Bhatia, H. S., Natarajan, P., Wolfe, R. S., Beilin, L. J., Nicholls, S. J., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.027 · Cited by 171
Tragante, V., Barnes, M. R., Ganesh, S. K., Lanktree, M. B., Guo, W., Franceschini, N., Smith, E. N., Johnson, T., Holmes, M. V., Padmanabhan, S., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.12.016 · Cited by 168
Self-citationBiomarkers for the Prediction of Type 2 Diabetes and Cardiovascular Disease
Herder, C., Karakas, M., & Koenig, W. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.93 · Cited by 168
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds
Tsimikas, S., & Marcovina, S. M. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.019 · Cited by 176
The role of lipoprotein (a) in chronic kidney disease
Hopewell, J. C., Haynes, R., & Baigent, C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r083626 · Cited by 172
Self-citationLipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment
Lampsas, S., Xenou, M., Oikonomou, E., Pantelidis, P., Lysandrou, A., Sarantos, S., Goliopoulou, A., Kalogeras, K., Tsigkou, V., Kalpis, A., et al. (2023) · Molecules · doi:10.3390/molecules28030969 · Cited by 162
“Moreover, several studies proclaim the detrimental effect of smaller apo(a) isoforms [44].”
Joshi, P. K., Pirastu, N., Kentistou, K. A., Fischer, K., Hofer, E., Schraut, K. E., Clark, D. W., Nutile, T., Barnes, C. L. K., Timmers, P. R. H. J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00934-5 · Cited by 161
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
“have unequivocally demonstrated that genetically elevated Lp(a) results in increased risk of CHD.(19,20) Thus, in principle, therapies that specifically reduce plasma Lp(a) concentrations”
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Nissen, S. E., Ni, W., Shen, X., Wang, Q., Navar, A. M., Nicholls, S. J., Wolski, K., Michael, L., Haupt, A., & Krege, J. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415818 · Cited by 159
Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?
Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.008 · Cited by 166
Burgess, S., Mason, A. M., Grant, A. J., Slob, E. A. W., Gkatzionis, A., Zuber, V., Patel, A., Tian, H., Liu, C., Haynes, W. G., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.12.017 · Cited by 174
“132,133 Genetic variants having a wide range of magnitudes of association with lipoprotein(a) levels were able to demonstrate a log-linear relationship between the genetic association with lipoprotein(a) levels and the ge-netic association with coronary heart disease risk, suggesting that the…”
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
Tsimikas, S., Moriarty, P. M., & Stroes, E. S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.051 · Cited by 154
Genes and Coronary Artery Disease
Roberts, R., & Stewart, A. F. R. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.062 · Cited by 185
Kamstrup, P. R., & Nordestgaard, B. G. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70064-0 · Cited by 161
Yeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine
Marcovina, S. M., Sirtori, C. R., Peracino, A. P., Gheorghiade, M., Borum, P. R., Remuzzi, G., & Ardehali, H. (2012) · Translational research · doi:10.1016/j.trsl.2012.10.006 · Cited by 163
“Furthermore, Mendelian randomization studies have established a casual role for Lp(a) in cardiovascular disease.(97,98) Lp(a) is a peculiar plasma macromolecule composed of a single low density lipoprotein-like molecule containing apolipoprotein B-100 and one molecule of a polymorphic protein called apo(a).”
Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour
Peden, J. F., & Farrall, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr384 · Cited by 167
“This is encouraged by the detection of a haplotype association with coronary disease (55) that subsequently was partially explained as a synthetic association to an LPA SNP (30).”
BackgroundInfluentialSelf-citationLPA Gene, Ethnicity, and Cardiovascular Events
Lee, S.-R., Prasad, A., Choi, Y.-S., Xing, C., Clopton, P., Witztum, J. L., & Tsimikas, S. (2017) · Circulation · doi:10.1161/circulationaha.116.024611 · Cited by 139
Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia
Ellis, K. L., Pérez de Isla, L., Alonso, R., Fuentes, F., Watts, G. F., & Mata, P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.037 · Cited by 147
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 155
Verbeek, R., Hoogeveen, R. M., Langsted, A., Stiekema, L. C. A., Verweij, S. L., Hovingh, G. K., Wareham, N. J., Khaw, K.-T., Boekholdt, S. M., Nordestgaard, B. G., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy334 · Cited by 145
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M. L., Lambert, G. C., Mach, F., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.04.012 · Cited by 150
Simony, S. B., Mortensen, M. B., Langsted, A., Afzal, S., Kamstrup, P. R., & Nordestgaard, B. G. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1023 · Cited by 152
Sattar, N. A., Preiss, D., Robinson, J. G., Djedjos, C. S., Elliott, M., Somaratne, R. M., Wasserman, S. M., & Raal, F. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00003-6 · Cited by 146
Gabay, C., McInnes, I. B., Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J., & Sattar, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207872 · Cited by 140
Vitamin D and high blood pressure: causal association or epiphenomenon?
Kunutsor, S. K., Burgess, S., Munroe, P. B., & Khan, H. M. (2013) · European Journal of Epidemiology · doi:10.1007/s10654-013-9874-z · Cited by 150
“Such MR investigations have been used to investigate the causal relevance of risk markers, such as C-reactive protein and lipoprotein (a), to risk of coronary heart disease in the absence of interventions that specifically modify levels of these risk markers [50, 51].”
BackgroundBenn, M., & Nordestgaard, B. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy045 · Cited by 130
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
Gilliland, T., Liu, Y., Mohebi, R., Miksenas, H., Haidermota, S., Wong, M. Y., Hu, X., Cristino, J. R., Browne, A., Plutzky, J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.050 · Cited by 145
Fattore, E., Bosetti, C., Brighenti, F., Agostoni, C., & Fattore, G. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.081190 · Cited by 138
“Despite the limited number of studies reporting this biomarker, this result is consistent with our knowledge on the strict genetic control of serum lipoprotein(a) concentrations (91).”
ResultProtective alleles and modifier variants in human health and disease
Harper, A. R., Nayee, S., & Topol, E. J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg4017 · Cited by 141
Lipoprotein apheresis to treat elevated lipoprotein (a)
Waldmann, E., & Parhofer, K. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r056549 · Cited by 131
Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1206 · Cited by 136
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 132
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Greco, A., Finocchiaro, S., Spagnolo, M., Faro, D. C., Mauro, M. S., Raffo, C., Sangiorgio, G., Imbesi, A., Laudani, C., Mazzone, P. M., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.069210 · Cited by 141
“7–9 Currently, awareness on the role of Lp(a) remains limited, and Lp(a) testing has not been widely adopted for estimating and stratifying the cardiovascular risk on a large scale.”
Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease
Cho, K. I., Sakuma, I., Sohn, I. S., Jo, S.-H., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.029 · Cited by 123
Berman, A. N., Biery, D. W., Besser, S. A., Singh, A., Shiyovich, A., Weber, B., Huck, D. M., Divakaran, S., Hainer, J. M., Kaur, G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.031 · Cited by 134
Ganesh, S. K., Arnett, D. K., Assimes, T. L., Basson, C. T., Chakravarti, A., Ellinor, P. T., Engler, M. B., Goldmuntz, E., Herrington, D. M., Hershberger, R. E., et al. (2013) · Circulation · doi:10.1161/01.cir.0000437913.98912.1d · Cited by 127
Davies, R. W., Wells, G. A., Stewart, A. F. R., Erdmann, J., Shah, S. H., Ferguson, J. F., Hall, A. S., Anand, S. S., Burnett, M. S., Epstein, S. E., et al. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.961243 · Cited by 125
Pearson‐Fuhrhop, K. M., Minton, B. R., Acevedo, D., Shahbaba, B., & Cramer, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061197 · Cited by 139
“Five polymorphisms known to influence brain dopamine neurotransmission were chosen for the current investigation, with their combined effect examined as a gene score, an approach that has been found useful for calculating genetic risk in several human disease settings [23,24,25].”
BackgroundEnas, E. A., Varkey, B., Dharmarajan, T. S., Paré, G., & Bahl, V. K. (2019) · Indian Heart Journal · doi:10.1016/j.ihj.2019.03.004 · Cited by 135
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective
Arsenault, B. J., & Kamstrup, P. R. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.015 · Cited by 132
Vinci, P., Girolamo, F. G. D., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., Biasinutto, C., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186721 · Cited by 139
“To date, only a few SNPs (including rs3798220 and rs10455872 SNPs) have shown a significant association with increased plasma Lp(a) levels and CVD [23].”
BackgroundDeshmukh, H. A., Colhoun, H. M., Johnson, T., McKeigue, P. M., Betteridge, D. J., Durrington, P. N., Fuller, J. H., Livingstone, S., Charlton-Menys, V., Neil, A., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p021113 · Cited by 125
“The Lp(a) raising genotype associated with the kringle repeat and high Lp(a) levels themselves have also been reported to be associated with increased cardiovascular risk in several studies [12,13,14,15,16].”
BackgroundPaige, E., Masconi, K. L., Tsimikas, S., Kronenberg, F., Santer, P., Weger, S., Willeit, J., Kiechl, S., & Willeit, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0520-z · Cited by 121
“However, this increased absolute risk of diabetes is considered to be low and does not outweigh the benefits of statins in reducing CVD events [43].”
BackgroundInfluentialStiekema, L. C. A., Prange, K. H. M., Hoogeveen, R. M., Verweij, S. L., Kroon, J., Schnitzler, J. G., Dzobo, K. E., Cupido, A. J., Tsimikas, S., Stroes, E. S. G., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa171 · Cited by 118
“Epidemiological and Mendelian randomization studies suggest an independent and causal relationship between elevated Lp(a) levels (above 50 mg/dL or 125 nmol/L) and CVD risk.(2,3) Previously, we demonstrated that healthy subjects with elevated Lp(a) have an activated innate immune system, characterized by pro-inflammat…”
BackgroundElevated Lipoprotein(a) and Risk of Atrial Fibrillation
Mohammadi-Shemirani, P., Chong, M., Narula, S., Perrot, N., Conen, D., Roberts, J. D., Thériault, S., Bossé, Y., Lanktree, M. B., Pigeyre, M., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.018 · Cited by 120
Genome-wide analysis yields new loci associating with aortic valve stenosis
Helgadottir, A., Thorleifsson, G., Gretarsdottir, S., Stefansson, O. A., Tragante, V., Thorolfsdottir, R. B., Jonsdottir, I., Bjornsson, T., Steinthorsdottir, V., Verweij, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03252-6 · Cited by 125
Self-citationMerki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124
“In addition to the size heterogeneity of apo(a) isoforms influencing plasma Lp(a) levels, it has been recently appreciated that additional genetic differences may play a role (12,22,23).”
BackgroundInfluentialVuorio, A. F., Watts, G. F., Schneider, W. J., Tsimikas, S., & Kovanen, P. T. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12981 · Cited by 127
Puri, R., Nissen, S. E., Arsenault, B. J., John, J. S., Riesmeyer, J. S., Ruotolo, G., McErlean, E. S., Menon, V., Cho, L., Wolski, K., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2413 · Cited by 123
Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort
Wong, N. D., Fan, W., Hu, X., Ballantyne, C. M., Hoogeveen, R. C., Tsai, M. Y., Browne, A., & Budoff, M. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.031 · Cited by 125
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.